Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
This study has been withdrawn prior to enrollment.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: December 11, 2007
Last updated: November 2, 2009
Last verified: December 2008
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|